Former FDA Commissioner Scott Gottlieb says FDA appears to be selectively enforcing compounding regulations to influence drug pricing, which he says could weaken FDA’s ability to regulate compounded drugs and erode its authority over compounding pharmacies. But Alliance for Pharmacy Compounding CEO Scott Brunner tells Inside Health Policy that tying compounded drug regulation to the drug pricing debate is misguided, noting FDA has not cited price or affordability in its statements or warning letters on compounded drugs. Gottlieb pointed...